Anixa Biosciences Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat Anixa Biosciences de winst en omzet met respectievelijk 9.5% en 75.2% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 24.4% per jaar.

Belangrijke informatie

9.5%

Groei van de winst

24.4%

Groei van de winst per aandeel

Biotechs winstgroei	42.4%
Inkomstengroei	75.2%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	19 Nov 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

DB:CY71 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
10/31/2027	N/A	-17	-16	-16	1
10/31/2026	N/A	-16	-16	-16	1
10/31/2025	N/A	-15	-15	-15	2
10/31/2024	N/A	-13	-46	-11	2
7/31/2024	N/A	-12	-8	-8	N/A
4/30/2024	N/A	-12	-7	-7	N/A
1/31/2024	0	-11	-7	-7	N/A
10/31/2023	0	-10	-6	-6	N/A
7/31/2023	0	-11	-6	-6	N/A
4/30/2023	0	-11	-6	-6	N/A
1/31/2023	N/A	-12	-7	-7	N/A
10/31/2022	N/A	-14	-6	-6	N/A
7/31/2022	0	-14	-6	-6	N/A
4/30/2022	0	-16	-6	-6	N/A
1/31/2022	0	-15	-5	-5	N/A
10/31/2021	1	-13	-5	-5	N/A
7/31/2021	1	-11	-5	-5	N/A
4/30/2021	1	-9	-5	-5	N/A
1/31/2021	1	-10	-5	-5	N/A
10/31/2020	N/A	-10	-6	-6	N/A
7/31/2020	N/A	-10	-6	-6	N/A
4/30/2020	N/A	-9	-5	-5	N/A
1/31/2020	0	-9	-6	-5	N/A
10/31/2019	0	-12	-5	-5	N/A
7/31/2019	0	-15	-5	-4	N/A
4/30/2019	1	-18	-5	-5	N/A
1/31/2019	1	-17	-4	-4	N/A
10/31/2018	1	-14	-4	-4	N/A
7/31/2018	1	-10	-4	-4	N/A
4/30/2018	1	-7	N/A	-4	N/A
1/31/2018	0	-5	N/A	-4	N/A
10/31/2017	0	-7	N/A	-4	N/A
7/31/2017	1	-6	N/A	-4	N/A
4/30/2017	0	-6	N/A	-3	N/A
1/31/2017	0	-7	N/A	-4	N/A
10/31/2016	0	-5	N/A	-3	N/A
7/31/2016	0	-5	N/A	-4	N/A
4/30/2016	0	-6	N/A	-3	N/A
1/31/2016	0	-7	N/A	-4	N/A
10/31/2015	0	-1	N/A	1	N/A
7/31/2015	2	-3	N/A	2	N/A
4/30/2015	3	-1	N/A	2	N/A
1/31/2015	4	-2	N/A	3	N/A
10/31/2014	4	-10	N/A	-2	N/A
7/31/2014	3	-9	N/A	-3	N/A
4/30/2014	1	-12	N/A	-3	N/A
1/31/2014	0	-12	N/A	-3	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CY71 de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CY71 de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CY71 de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat CY71 volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat CY71 volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CY71 naar verwachting over 3 jaar hoog zal zijn

Anixa Biosciences Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Recent updates

Anixa Biosciences, Inc Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting

Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

Anixa Biosciences, Inc. Announces Submission of Protocol Amendment for CAR-T Trial

Lead Independent Director recently bought €78k worth of stock

Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology

Anixa Biosciences, Inc. (NasdaqCM:ANIX) announces an Equity Buyback for $5 million worth of its shares.

Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial

CEO, Chairman & Co-Chair of CBAB recently bought €56k worth of stock

New major risk - Revenue and earnings growth

Anixa Biosciences, Inc. Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board

CEO, Chairman & Co-Chair of CBAB recently bought €89k worth of stock

New major risk - Revenue and earnings growth

Anixa Biosciences, Inc., Annual General Meeting, Mar 21, 2024

Anixa Biosciences, Inc. Announces Japanese Patent on Ovarian Cancer Vaccine Technology

New major risk - Share price stability

New minor risk - Shareholder dilution

New major risk - Share price stability

Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine

Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology

Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology

Anixa Biosciences, Inc. Appoints Mark A. Goldberg, Md, to Its Cancer Business Advisory Board

Anixa Biosciences, Inc. Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial

New major risk - Share price stability

Anixa Biosciences, Inc. Establishes Cancer Business Advisory Board

Anixa Biosciences, Inc. Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial

Press Release: Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology

Now 40% undervalued after recent price drop

Anixa Biosciences, Inc., Annual General Meeting, Mar 09, 2023

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine

Insufficient new directors

Insufficient new directors

Anixa Biosciences Inc. Announces Commencement of Phase 1B Trial of Its Breast Cancer Vaccine At Cleveland Clinic

Anixa Biosciences Announces Treatment of First Patient in Its Ovarian Cancer Car-T Clinical Trial

Anixa Biosciences, Inc. Announces Management Changes

Anixa Biosciences, Inc. Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center

Anixa Biosciences, Inc., Annual General Meeting, Mar 10, 2022

Anixa Biosciences, Inc., Annual General Meeting, Mar 10, 2022

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine

Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor

Chairman recently bought €53k worth of stock

Anixa Biosciences and Molgenie Announce That Their Covid-19 Compounds Are Expected to Be Effective Against the Omicron Variant

Lead Independent Director recently bought €75k worth of stock

Anixa Biosciences' Covid-19 Compounds Expected to Be Effective Against the Delta Variant

Anixa Biosciences, Inc. Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine Technology

Board Member recently bought €70k worth of stock

Lead Independent Director recently bought €73k worth of stock

Independent Director has left the company

Independent Director has left the company

Anixa Biosciences, Inc Receives Additional Information Request from US FDA for CAR-T IND Application

Lead Independent Director recently bought €185k worth of stock

New 90-day high: €4.72

Anixa Biosciences, Inc. Announces European Patent Issued for Its CAR-T Cancer Therapy

Anixa Biosciences, Inc. Begins Animal Testing of Covid-19 Therapeutic Candidates

New 90-day high: €3.88

New 90-day high: €2.68

Anixa Biosciences and Cleveland Clinic Announce FDA Clearance to Initiate Clinical Trial of Breast Cancer Vaccine

Anixa Biosciences, Inc. Covid-19 Therapy Demonstrates Comparable Potency to Remdesivir in Pre-Clinical Testing

New 90-day high: €2.46

Anixa Biosciences, Inc. Announces Licensing Agreement with Cleveland Clinic for Ovarian Cancer Vaccine Technology

Lead Independent Director recently bought €70k worth of stock

New 90-day low - €1.67

Anixa Biosciences, Inc.(NasdaqCM:ANIX) dropped from Russell Microcap Value Index

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven